A study involving ganirelix was registered on clinicaltrials.gov as of August 3, 2026. The trial is titled "Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study."
The study is listed as a prospective comparative observational study, with the registry identifier NCT07732348. According to the registry entry, the trial status is not yet recruiting. No phase designation was provided in the listing.
The study design compares an oral GnRH antagonist, linzagolix, against an injectable GnRH antagonist, identified as ganirelix, alongside progestin-primed ovarian stimulation, in the context of controlled ovarian stimulation for in vitro fertilization. No enrollment numbers, timelines, or outcome data have been posted at this stage.
Because the trial has not yet begun recruiting, no results or interim findings are available. This brief reflects only the registration details as listed on clinicaltrials.gov at the time of this report. Readers can consult the compound overview for additional background on ganirelix.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07732348"]